Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | MLYCD | O95822 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6230938 | 0.91 | SMN1; SMN2 (0.64) | SMN1; SMN2ALOX5MLYCDMEN1KMT2A | |
| SCHEMBL6228355 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2ALOX5MLYCDMEN1KMT2A | |
| SCHEMBL6228524 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2ALOX5MLYCDMEN1KMT2A | |
| SCHEMBL14969389 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1KMT2ATP53CYP4F2 | |
| Benzene SCHEMBL29172594 | 0.80 | CYP4F2 (0.68) | SMN1; SMN2ALOX5MEN1KMT2ATDP1 | |
| SCHEMBL6332632 | 0.79 | TRPM8 (0.52) | SMN1; SMN2ALOX5MEN1KMT2A | |
| SCHEMBL18011670 | 0.79 | CYP4F2 (0.62) | SMN1; SMN2ALOX5MEN1KMT2ATDP1 | |
| SCHEMBL6228297 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2ALOX5MLYCDMEN1KMT2A | |
| SCHEMBL6229292 | 0.77 | ALOX5 (0.52) | SMN1; SMN2ALOX5MEN1KMT2ATDP1 | |
| SCHEMBL2293786 | 0.77 | CYP4F2 (0.72) | SMN1; SMN2MEN1KMT2ATDP1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900219-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1513534-A2 | COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030220356-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003084544-A2 | COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220356-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | SMN1; SMN2 4558/4885ALOX5 3356/4885MLYCD 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.